license
-
MabCure signs license agreement with Biotech Investment Corp
MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15 percent of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5 percent on revenues.
license | 07 February 2012
-
Phosphagenics licenses Diclofenac gel for Indian market
Phosphagenics has licensed TPM/diclofenac, its topical non-steroidal pain formulation, to Themis Medicare of Mumbai for the Indian market. This represents Phosphagenics’ first commercial deal in India and its first licensing agreement of its diclofenac product. Under the terms of the agreement, Themis Medicare is committed to pay Phosphagenics an undisclosed up-front fee and double-digit royalty payments on sales.
license | 06 January 2012
-
Daiichi Sankyo to license ARQ 092 from ArQule
ArQule and Daiichi Sankyo announced the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors. Under the license agreement, Daiichi Sankyo will obtain exclusive rights for development, manufacturing and marketing of ARQ 092 on a worldwide basis.
license | 01 December 2011
-
BeiGene in-licenses two clinical-stage oncology compounds
BeiGene will collaborate with Janssen in phase III clinical trials in melanoma and explore additional solid tumor indications in solid tumors prevalent in China and Asia.
license | 15 October 2011
-
Sanofi Pasteur acquires exclusive, worldwide license for acne vaccine and treatment
Pre-clinical vaccine was developed by researchers at the University of California, San Diego.
license | 21 September 2011
-
Boehringer Ingelheim licenses ProBioGen's GlymaxX technology
Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive licensing agreement regarding ProBioGen’s GlymaxX technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (…
license | 11 August 2011
-
RaQualia announces license agreement with CJ CheilJedang
RaQualia Pharma Inc announced the signing of a license agreement with CJ CheilJedang Co granting CJ exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 Partial Agonist (RQ-00000010) in Korea, China, Taiwan, India and Southeast…
license | 01 August 2011
-
Array BioPharma licenses cancer drug to ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc announced a license agreement to develop Array’s HER2 / EGFR inhibitor, ARRY-543, currently entering phase 2 development for solid tumors. Under the agreement, ASLAN will fund and globally de…
license | 14 July 2011
-
Procognia signs license agreement with CTCLS
Procognia announced that, on July 11th, 2011, the company signed an agreement with CTC Laboratory System Corporation (CTCLS). According to this agreement, Procognia will grant CTCLS a non-exclusive license to sell, distribute and market the glycoanal…
license | 12 July 2011
-
Allergan and Molecular Partners enter into license agreement for MP0112
Allergan Inc and Molecular Partners AG announced that they have entered into a license agreement for MP0112, a phase 2 proprietary therapeutic DARPin protein targeting VEGF under investigation for the treatment of retinal diseases. Under the agre…
license | 05 May 2011
